All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2018-03-07T15:16:21.000Z

Retrospective analysis of WM patient outcomes receiving combination therapy and rituximab maintenance

Mar 7, 2018
Share:

Bookmark this article

A research paper was published on 28 December 2017 in the British Journal of Haematology presenting study results of combined therapy and rituximab maintenance in patients with Waldenström macroglobulinemia (WM) by Jorge Castillo, Dana-Farber Cancer Institute, Massachusetts, and colleagues.

One hundred and eighty-two WM patients receiving specified primary therapy combinations were included in this retrospective study from a database between January 2005 and December 2016. Patients received primary therapy with either bendamustine and rituximab (Benda-R, n = 57), bortezomib-dexamethasone-rituximab (BDR, n = 87) or cyclophosphamide-dexamethasone-rituximab (CDR, n = 38). After primary therapy, 116 patients (64%) received maintenance rituximab.

Key Findings

  • Progression-free survival (PFS) results:
    • Median overall = 5.8 years (95% CI, 4.9–6.8 years)
    • Benda-R median = 5.5 years (95% CI, 4.9–not reached (NR))
    • BDR median = 5.8 years (95% CI, 4.4–7.4 years)
    • CDR median = 4.9 years (95% CI, 2.8–7.0 years)
    • Median PFS for patients who received R-maintenance and who did not = 6.8 years (95% CI, 5.9–NR) vs 8 years (95% CI, 2.1–4.1 years), respectively
  • Overall survival (OS) results:
    • Median overall follow-up time = 3.5 years (95% CI, 3–4 years)
    • Estimated overall 5- and 10-year OS = 92% (95% CI, 84–96%) and 79% (95% CI, 61–89%), respectively
    • Median overall OS = NR
    • Benda-R estimated 5-year = 95% (95% CI, 81–99%)
    • BDR estimated 5-year = 96% (95% CI, 85–99%)
    • CDR estimated 5-year = 81% (95% CI, 60–92%)

The authors found from their results and exploratory analyses that Benda-R and BDR produced higher response rates and longer PFS than CDR. Additionally, they noted that OS appeared longer in patients treated with BDR compared with CDR. Superior OS and PFS was found in patients receiving rituximab maintenance.

The authors concluded that from their study, they found Benda-R and BDR a viable primary therapy option for WM patients due to faster and better duration of response. They also recommended that since the primary therapy options explored in the study were not curative, “treatment of patients with WM has to be personalized,” and taking into account, “the patient’s disease presentation, the efficacy and toxicity of the regimen to be used and the patient’s preferences and goals of care.”

  1. Castillo JJ. et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. British Journal of Haematology. 2018 Feb 22.DOI: 10.1111/bjh.15148. [Epub ahead of print]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 48 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox